Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Equity Income (2019 - 2025)

Ultragenyx Pharmaceutical has reported Equity Income over the past 7 years, most recently at $678000.0 for Q3 2025.

  • Quarterly Equity Income changed 0.0% to $678000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$1.0 million through Sep 2025, down 144.62% year-over-year, with the annual reading at -$1.1 million for FY2024, 380.86% down from the prior year.
  • Equity Income was $678000.0 for Q3 2025 at Ultragenyx Pharmaceutical, up from -$9000.0 in the prior quarter.
  • Over five years, Equity Income peaked at $25.7 million in Q3 2021 and troughed at -$31.0 million in Q2 2021.
  • The 5-year median for Equity Income is -$334000.0 (2023), against an average of -$3.2 million.
  • The largest YoY upside for Equity Income was 1221.56% in 2024 against a maximum downside of 1629.12% in 2024.
  • A 5-year view of Equity Income shows it stood at -$16.1 million in 2021, then skyrocketed by 111.43% to $1.8 million in 2022, then increased by 2.66% to $1.9 million in 2023, then crashed by 181.95% to -$1.5 million in 2024, then soared by 143.8% to $678000.0 in 2025.
  • Per Business Quant, the three most recent readings for RARE's Equity Income are $678000.0 (Q3 2025), -$9000.0 (Q2 2025), and -$157000.0 (Q1 2025).